Risk Score for Kawasaki Disease (HART KD®, KawasakiDx)
Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is an acute, self-limited vasculitis that predominantly affects children under 5 years of age. It is the leading cause of acquired heart disease in children in developed countries, with a prevalence of 10–20 cases per 100,000 children under 5. The etiology remains unclear, though genetic predisposition, environmental exposures, and infectious triggers are implicated. The hallmark feature of KD is vasculitis of medium-sized arteries, particularly the coronary arteries. Untreated disease may result in coronary artery aneurysms, which can cause myocardial infarction or sudden death. KD typically progresses through three phases: • Acute phase (1–2 weeks): Prolonged fever (>39 °C or 102.2 °F for >5 days), conjunctivitis, rash, extremity changes (edema, erythema), and cervical lymphadenopathy. • Subacute phase (2–4 weeks): Resolution of fever, but risk of coronary artery aneurysm development. • Convalescent phase (4–8 weeks): Resolution of systemic symptoms, but coronary abnormalities may persist. Intravenous immunoglobulin (IVIg) is the standard treatment and significantly reduces coronary aneurysm risk. However, 13–21% of patients are resistant to IVIg, putting them at higher risk of vascular complications. To improve diagnosis and predict IVIg resistance, several risk scoring systems have been developed, including the Harada (HS), Kobayashi (KS), Egami (ES), Sano (SS), and Formosa (FS) scores. These systems incorporate laboratory and clinical parameters such as CRP, liver enzymes, sodium, albumin, neutrophil percentage, platelet count, and bilirubin levels to stratify children into high-risk vs. low-risk categories.
| Scheme | Parameters | Scoring | Sensitivity / Specificity | PPV / NPV |
|---|---|---|---|---|
| Kobayashi | AST ≥100; Na <133 mmol/L; fever ≤4 days; neutrophils ≥80%; CRP ≥10 mg/dL; age ≤1 yr; platelets <300k | High risk ≥4 | 86% / 67% | 43% / 95% |
| Egami | ALT ≥80; fever ≤4 days; CRP ≥8 mg/dL; age <6 mo; platelets ≤300k | High risk ≥3 | 78% / 76% | 32% / 96% |
| Sano | AST ≥200; bilirubin ≥0.9 mg/dL; CRP ≥7 mg/dL | High risk ≥2 | 77% / 86% | 59% / 94% |
| Harada | WBC >12k; platelets <350k; CRP >3 mg/dL; Hct <35%; albumin <3.5 g/dL; age ≤12 mo; male sex | Not specified | – | – |
| Formosa | Lymphadenopathy; neutrophil/WBC ≥60%; albumin <3.5 g/dL | Not specified | – | – |
The KawasakiDx test measures the expression of interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1) in blood using quantitative reverse transcription polymerase chain reaction (RT-qPCR). Results are reported as a risk score for Kawasaki disease.
- As an aid in the diagnosis of Kawasaki disease (pediatric febrile illness)
- Differential diagnosis of coronary artery aneurysm in children
- Identifies patients at higher risk of IVIg resistance
- High-risk scores: Greater likelihood of KD and higher chance of IVIg resistance; requires aggressive management and monitoring.
- Low-risk scores: Lower likelihood of IVIg resistance; patients more likely to respond to standard IVIg therapy.
| Scheme | Parameters | Scoring | Sensitivity / Specificity | PPV / NPV |
|---|---|---|---|---|
| Kobayashi | AST ≥100; Na <133 mmol/L; fever ≤4 days; neutrophils ≥80%; CRP ≥10 mg/dL; age ≤1 yr; platelets <300k | High risk ≥4 | 86% / 67% | 43% / 95% |
| Egami | ALT ≥80; fever ≤4 days; CRP ≥8 mg/dL; age <6 mo; platelets ≤300k | High risk ≥3 | 78% / 76% | 32% / 96% |
| Sano | AST ≥200; bilirubin ≥0.9 mg/dL; CRP ≥7 mg/dL | High risk ≥2 | 77% / 86% | 59% / 94% |
| Harada | WBC >12k; platelets <350k; CRP >3 mg/dL; Hct <35%; albumin <3.5 g/dL; age ≤12 mo; male sex | Not specified | – | – |
| Formosa | Lymphadenopathy; neutrophil/WBC ≥60%; albumin <3.5 g/dL | Not specified | – | – |
Whole blood EDTA or Serum in SST.
Stability
- Ambient: 48 hours
- Refrigerated: 7 days
- Frozen: 30 days
- Clin Exp Pediatr. 2024 Aug;67(8):405-414. [PMID: 39048087]
- Anatol J Cardiol. 2020 Aug;24(2):97-106. [PMID: 32749248]
- J Pediatr. 2011 May;158(5):831-835.e3. [PMID: 21168857]
- Pediatric Health Med Ther. 2019 Oct 30;10:131-139. [PMID: 31802968]